Denosumab Shows Immunomodulatory Effects in HER2-Negative Early Breast Cancer

The D-BIOMARK (搜索)搜索该词条 clinical trial has revealed that denosumab查看药品详情, a monoclonal antibody targeting RANKL (搜索)搜索该靶点, demonstrates immunomodulatory effects in patients with HER2-negative (搜索)搜索该疾病 early breast cancer (搜索)搜索该疾病, potentially expanding its therapeutic applications beyond bone health.

The randomized window-of-opportunity trial enrolled 58 evaluable patients with early-stage HER2-negative (搜索)搜索该疾病 breast cancer (搜索)搜索该疾病 who were candidates for tumor excision as their first therapeutic approach. Patients were randomized 2:1 to either receive two subcutaneous doses of denosumab查看药品详情 (120 mg each) administered 7 days apart or no treatment in the control group.

Denosumab's Effect on Tumor Biology

The primary endpoints of the trial were to assess changes in tumor cell proliferation (Ki67 (搜索)搜索该靶点) and apoptosis (cleaved caspase-3) between diagnostic biopsy and surgical specimens. Contrary to expectations based on preclinical studies, denosumab查看药品详情 did not reduce tumor cell proliferation or increase apoptosis in early breast cancer (搜索)搜索该疾病 patients.

"Once the tumor is established, the anti-proliferative and pro-apoptotic effects may be lost," the researchers noted, explaining the discrepancy between preclinical findings and clinical results. This suggests that RANK (搜索)搜索该靶点 signaling may be more critical in tumor initiation rather than in established tumors.

Immunomodulatory Effects Observed

Notably, the trial revealed a statistically significant increase in tumor-infiltrating lymphocytes (搜索)搜索该靶点 (TILs) in patients treated with denosumab查看药品详情. This increase was particularly evident in luminal B-like (搜索)搜索该疾病 tumors and was observed in both pre-menopausal and post-menopausal patients.

While the control group showed a similar trend toward increased TILs, it did not reach statistical significance, suggesting that denosumab查看药品详情 may enhance immune infiltration in the tumor microenvironment. The researchers acknowledged that the inflammatory effect induced by the biopsy or differences between biopsy and surgical specimens might have contributed to variations in both groups.

RANK and RANKL Expression Patterns

The study also provided valuable insights into RANK (搜索)搜索该靶点 and RANKL (搜索)搜索该靶点 expression patterns in breast cancer (搜索)搜索该疾病. Approximately 34.5% of tumors expressed RANK and 30% expressed RANKL in tumor cells at baseline, slightly higher than previously reported in the literature, particularly in luminal tumors.

RANK (搜索)搜索该靶点 protein expression in tumor cells correlated with aggressive tumor characteristics, including high Ki67 (搜索)搜索该靶点 levels, low estrogen receptor expression, and high histological grade. A novel finding was the association between RANK expression in the tumor stroma and high levels of tumor proliferation, which remained significant even when analyzing only luminal tumors.

Despite these correlations, baseline RANK (搜索)搜索该靶点 or RANKL (搜索)搜索该靶点 expression did not predict denosumab查看药品详情-driven changes in TILs, suggesting that other factors may influence the immunomodulatory response to denosumab.

Systemic Effects and Safety Profile

The blockade of the RANK (搜索)搜索该靶点-RANKL (搜索)搜索该靶点 pathway was confirmed by a significant drop in serum free RANKL levels in the experimental group, while no changes were observed in the control group. However, the serum levels of bone resorption markers did not change significantly, possibly due to technical limitations or the short interval between treatment and assessment.

Denosumab查看药品详情 demonstrated an acceptable safety profile, with the most common adverse events being grade 1 or 2 bone pain (27.03%), grade 1 asthenia (10.81%), and grade 1 pain at the infusion site (8.10%). One case of osteonecrosis of the jaw was reported 11 months after treatment in a heavy smoker, classified as grade 3 toxicity.

Implications for Future Research

The findings from D-BIOMARK (搜索)搜索该词条 suggest potential applications for denosumab查看药品详情 as an immune response enhancer in breast cancer (搜索)搜索该疾病 treatment, particularly in combination with immunotherapy.

"Could denosumab查看药品详情 improve these results?" the researchers questioned, referring to the modest pathological complete response rates observed with immunotherapy in luminal B-like (搜索)搜索该疾病 tumors. "A booster given by denosumab allowing new combinations of treatments in a tumor microenvironment that would otherwise be cold is of clinical interest."

The researchers noted that preclinical data already show synergy between immune checkpoint inhibitors and inhibitors of RANK (搜索)搜索该靶点 signaling in solid tumors, and clinical trials combining these approaches in melanoma and renal cell carcinoma have shown promising results.

Study Limitations and Strengths

The study had several limitations, including a small sample size that limited subgroup analyses, statistical imbalance due to the 2:1 randomization, and tumor heterogeneity, particularly affecting the triple-negative breast cancer (搜索)搜索该疾病 cohort.

However, the inclusion of a control group and a larger sample size compared to previous studies allowed the researchers to generate hypotheses regarding denosumab查看药品详情's role as an immune modulator not only in premenopausal women but also in postmenopausal women.

The D-BIOMARK (搜索)搜索该词条 trial provides important clinical validation of preclinical observations and contributes to a better understanding of denosumab查看药品详情's biological effects beyond bone health, potentially paving the way for new therapeutic strategies in breast cancer (搜索)搜索该疾病 treatment.